Lower buprenorphine elimination rate constant is associated with lower opioid use

Hesham Farouk Elarabi; Amanda J Lee; Abdu Adem; Abuelgasim Elrasheed; John Marsden; Hamad Al Ghaferi

doi:10.1007/s00213-022-06202-9

Lower buprenorphine elimination rate constant is associated with lower opioid use

Hesham Farouk Elarabi, Amanda J Lee, Abdu Adem, Abuelgasim Elrasheed, John Marsden, Hamad Al Ghaferi

Research output: Contribution to journal › Article › peer-review

4 Downloads (Pure)

Abstract

BACKGROUND: Opioid craving is suggested to correlate with the rate of reduction in buprenorphine (BUP) plasma levels. No studies explored Buprenorphine elimination rate constant (BUP EL.R) as a predictor of opioid use or retention in BUP treatment.

METHODS: Analysis was performed using data from a randomized controlled trial of 141 adults with opioid use disorder (OUD) randomized to Incentivized Adherence and Abstinence monitoring (I-AAM; experimental (n = 70) and treatment-as-usual; control (n = 71). In the I-AAM, structured access to unsupervised BUP doses was provided up to 28 days contingent of adherence measured by Therapeutic Drug Monitoring and abstinence by Urinary Drug Screens (UDS). In contrast, the treatment-as-usual (control) provided unstructured access to unsupervised doses was provided for up to 14 days considering UDS results. The primary outcome was percentage negative UDS. The secondary outcome, retention in treatment, was continuous enrollment in the study and analysis was via intention-to-treat. Significant bivariate correlations with the outcomes were adjusted for group allocation.

RESULTS: A significant negative correlation between BUP EL.R and percentage negative opioid screens (Pearson correlation coefficient - 0.57, p < 0.01) was found. After adjusting for trial group, BUP EL.R was shown to be an independent predictor of percentage negative opioid screens (Standardized Beta Coefficient - 0.57, 95% CI - 221.57 to - 97.44, R 2 0.322).

CONCLUSION: BUP EL.R predicted 32.2% of the variation in percentage negative opioid UDS and may serve as a potential promising tool in precision medicine of BUP treatment. Higher buprenorphine elimination is associated with higher positive opioid urine screens during treatment.

TRIAL REGISTRATION: ISRCTN41645723 retrospectively registered on 15/11/2015.

Original language	English
Pages (from-to)	3213-3221
Number of pages	9
Journal	Psychopharmacology
Volume	239
Issue number	10
Early online date	12 Aug 2022
DOIs	https://doi.org/10.1007/s00213-022-06202-9
Publication status	Published - Oct 2022

Bibliographical note

Acknowledgements
The authors would like to thank the Scholarship Office (SCO) at the Ministry of Presidential Affairs in the UAE for the educational support provided to complete this work. The authors would like to acknowledge the support provided by the National Rehabilitation Center and efforts of the investigators participating in the parent clinical trial.

Keywords

Adult
Analgesics, Opioid/therapeutic use
Buprenorphine/therapeutic use
Humans
Narcotic Antagonists/therapeutic use
Opioid-Related Disorders/drug therapy
Treatment Outcome

Access to Document

10.1007/s00213-022-06202-9

Elarabi_etal_P_Lower_Buprenorphine_Elimination_VOR
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Licence: CC BY

Cite this

@article{0992baef5cfc44348cae2d60f088e531,

title = "Lower buprenorphine elimination rate constant is associated with lower opioid use",

abstract = "BACKGROUND: Opioid craving is suggested to correlate with the rate of reduction in buprenorphine (BUP) plasma levels. No studies explored Buprenorphine elimination rate constant (BUP EL.R) as a predictor of opioid use or retention in BUP treatment.METHODS: Analysis was performed using data from a randomized controlled trial of 141 adults with opioid use disorder (OUD) randomized to Incentivized Adherence and Abstinence monitoring (I-AAM; experimental (n = 70) and treatment-as-usual; control (n = 71). In the I-AAM, structured access to unsupervised BUP doses was provided up to 28 days contingent of adherence measured by Therapeutic Drug Monitoring and abstinence by Urinary Drug Screens (UDS). In contrast, the treatment-as-usual (control) provided unstructured access to unsupervised doses was provided for up to 14 days considering UDS results. The primary outcome was percentage negative UDS. The secondary outcome, retention in treatment, was continuous enrollment in the study and analysis was via intention-to-treat. Significant bivariate correlations with the outcomes were adjusted for group allocation.RESULTS: A significant negative correlation between BUP EL.R and percentage negative opioid screens (Pearson correlation coefficient - 0.57, p < 0.01) was found. After adjusting for trial group, BUP EL.R was shown to be an independent predictor of percentage negative opioid screens (Standardized Beta Coefficient - 0.57, 95% CI - 221.57 to - 97.44, R 2 0.322). CONCLUSION: BUP EL.R predicted 32.2% of the variation in percentage negative opioid UDS and may serve as a potential promising tool in precision medicine of BUP treatment. Higher buprenorphine elimination is associated with higher positive opioid urine screens during treatment.TRIAL REGISTRATION: ISRCTN41645723 retrospectively registered on 15/11/2015.",

keywords = "Adult, Analgesics, Opioid/therapeutic use, Buprenorphine/therapeutic use, Humans, Narcotic Antagonists/therapeutic use, Opioid-Related Disorders/drug therapy, Treatment Outcome",

author = "Elarabi, {Hesham Farouk} and Lee, {Amanda J} and Abdu Adem and Abuelgasim Elrasheed and John Marsden and {Al Ghaferi}, Hamad",

note = "Acknowledgements The authors would like to thank the Scholarship Office (SCO) at the Ministry of Presidential Affairs in the UAE for the educational support provided to complete this work. The authors would like to acknowledge the support provided by the National Rehabilitation Center and efforts of the investigators participating in the parent clinical trial.",

year = "2022",

month = oct,

doi = "10.1007/s00213-022-06202-9",

language = "English",

volume = "239",

pages = "3213--3221",

journal = "Psychopharmacology",

issn = "0033-3158",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - Lower buprenorphine elimination rate constant is associated with lower opioid use

AU - Elarabi, Hesham Farouk

AU - Lee, Amanda J

AU - Adem, Abdu

AU - Elrasheed, Abuelgasim

AU - Marsden, John

AU - Al Ghaferi, Hamad

N1 - Acknowledgements The authors would like to thank the Scholarship Office (SCO) at the Ministry of Presidential Affairs in the UAE for the educational support provided to complete this work. The authors would like to acknowledge the support provided by the National Rehabilitation Center and efforts of the investigators participating in the parent clinical trial.

PY - 2022/10

Y1 - 2022/10

N2 - BACKGROUND: Opioid craving is suggested to correlate with the rate of reduction in buprenorphine (BUP) plasma levels. No studies explored Buprenorphine elimination rate constant (BUP EL.R) as a predictor of opioid use or retention in BUP treatment.METHODS: Analysis was performed using data from a randomized controlled trial of 141 adults with opioid use disorder (OUD) randomized to Incentivized Adherence and Abstinence monitoring (I-AAM; experimental (n = 70) and treatment-as-usual; control (n = 71). In the I-AAM, structured access to unsupervised BUP doses was provided up to 28 days contingent of adherence measured by Therapeutic Drug Monitoring and abstinence by Urinary Drug Screens (UDS). In contrast, the treatment-as-usual (control) provided unstructured access to unsupervised doses was provided for up to 14 days considering UDS results. The primary outcome was percentage negative UDS. The secondary outcome, retention in treatment, was continuous enrollment in the study and analysis was via intention-to-treat. Significant bivariate correlations with the outcomes were adjusted for group allocation.RESULTS: A significant negative correlation between BUP EL.R and percentage negative opioid screens (Pearson correlation coefficient - 0.57, p < 0.01) was found. After adjusting for trial group, BUP EL.R was shown to be an independent predictor of percentage negative opioid screens (Standardized Beta Coefficient - 0.57, 95% CI - 221.57 to - 97.44, R 2 0.322). CONCLUSION: BUP EL.R predicted 32.2% of the variation in percentage negative opioid UDS and may serve as a potential promising tool in precision medicine of BUP treatment. Higher buprenorphine elimination is associated with higher positive opioid urine screens during treatment.TRIAL REGISTRATION: ISRCTN41645723 retrospectively registered on 15/11/2015.

AB - BACKGROUND: Opioid craving is suggested to correlate with the rate of reduction in buprenorphine (BUP) plasma levels. No studies explored Buprenorphine elimination rate constant (BUP EL.R) as a predictor of opioid use or retention in BUP treatment.METHODS: Analysis was performed using data from a randomized controlled trial of 141 adults with opioid use disorder (OUD) randomized to Incentivized Adherence and Abstinence monitoring (I-AAM; experimental (n = 70) and treatment-as-usual; control (n = 71). In the I-AAM, structured access to unsupervised BUP doses was provided up to 28 days contingent of adherence measured by Therapeutic Drug Monitoring and abstinence by Urinary Drug Screens (UDS). In contrast, the treatment-as-usual (control) provided unstructured access to unsupervised doses was provided for up to 14 days considering UDS results. The primary outcome was percentage negative UDS. The secondary outcome, retention in treatment, was continuous enrollment in the study and analysis was via intention-to-treat. Significant bivariate correlations with the outcomes were adjusted for group allocation.RESULTS: A significant negative correlation between BUP EL.R and percentage negative opioid screens (Pearson correlation coefficient - 0.57, p < 0.01) was found. After adjusting for trial group, BUP EL.R was shown to be an independent predictor of percentage negative opioid screens (Standardized Beta Coefficient - 0.57, 95% CI - 221.57 to - 97.44, R 2 0.322). CONCLUSION: BUP EL.R predicted 32.2% of the variation in percentage negative opioid UDS and may serve as a potential promising tool in precision medicine of BUP treatment. Higher buprenorphine elimination is associated with higher positive opioid urine screens during treatment.TRIAL REGISTRATION: ISRCTN41645723 retrospectively registered on 15/11/2015.

KW - Adult

KW - Analgesics, Opioid/therapeutic use

KW - Buprenorphine/therapeutic use

KW - Humans

KW - Narcotic Antagonists/therapeutic use

KW - Opioid-Related Disorders/drug therapy

KW - Treatment Outcome

U2 - 10.1007/s00213-022-06202-9

DO - 10.1007/s00213-022-06202-9

M3 - Article

C2 - 35953563

SN - 0033-3158

VL - 239

SP - 3213

EP - 3221

JO - Psychopharmacology

JF - Psychopharmacology

IS - 10

ER -

Lower buprenorphine elimination rate constant is associated with lower opioid use

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this